Dr. Mathieu Epardaud is an immunologist with over 25 years of experience in vaccinology and immunotherapy. Since 2018, he has served as a senior scientist in the BioMAP team (UMR ISP 1282, INRAE & University of Tours), focusing on mucosal vaccine strategies and anti-cancer immunotherapies.
He is a lead scientist behind the intranasal vaccine platform currently in clinical evaluation with a COVID-19 candidate (NCT06821126) and co-founded LoValTech (2022), supporting translational development, regulatory activities, and industrial partnerships for mucosal vaccines. Coordinates the InHEALation project (2025–2028, ANRS-MIE/PEPR), which compares nasal and pulmonary spray delivery of influenza vaccines in preclinical models to enhance mucosal and systemic immune memory against seasonal and pandemic strains.
